2,7-Diazabicyclo[4.2.0]octane | 51392-74-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2,7-Diazabicyclo[4.2.0]octane
• CAS: 51392-74-6
• 化学式: C₆H₁₂N₂
• mdl: MFCD19226952
• 分子量: 112.17
• InChiKey: KNLOUXALILBKPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20150344489A1

  公开（公告）日：2015-12-03

  The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.

  本发明涉及公式I的新型取代氧吲哚衍生物，其中变量如权利要求和描述中所定义。该发明还涉及包含化合物I的药物组合物，以及它们用于治疗与加压素相关的疾病。
• [EN] CDK4/6 INHIBITORS AND USE THEREOF<br/>[FR] INHIBITEURS DE CDK4/6 ET LEUR UTILISATION
  申请人：BEIJING XUANYI PHARMASCIENCES CO LTD

  公开号：WO2019035008A1

  公开（公告）日：2019-02-21

  The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R1, R2, R3a, R3b, R5, R6, X1, X2, Y and n are described herein.

  本公开涉及式(I)的化合物，或其药用可接受的盐、溶剂合物、立体异构体或互变异构体，包括化合物(A)或化合物(B)的药物组合物，以及所述化合物和组合物的使用，其中R1、R2、R3a、R3b、R5、R6、X1、X2、Y和n如本文所述。
• [EN] HETEROCYCLIC COMPOUNDS, PREPARATION METHODS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
  申请人：INVENTISBIO SHANGHAI LTD

  公开号：WO2020233592A1

  公开（公告）日：2020-11-26

  Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

  本文提供了新颖的化合物，例如具有化学式(I)或化学式(II)的化合物，或其药用可接受的盐。本文还提供了制备这些化合物的方法以及使用这些化合物的方法，例如，在细胞中抑制KRAS G12C，和/或用于治疗各种癌症，如胰腺癌、子宫内膜癌、结肠癌或肺癌（例如非小细胞肺癌）。
• [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
  申请人：HARVARD COLLEGE

  公开号：WO2015103583A1

  公开（公告）日：2015-07-09

  Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.

  本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II')，以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
• HETEROCYCLIC-CARBONYL-DIAZABICYCLOALKANES AS MODULATORS OF THE NEURONAL NICOTINIC ACETYLCHOLINE ALPHA 4 BETA 2, SUBTYPE RECEPTOR FOR THE TREATMENT OF CNS RELATED DISORDERS
  申请人：Hammond Philip S.

  公开号：US20100144700A1

  公开（公告）日：2010-06-10

  A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryl group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle.

  化合物的化学式为1：A-C（O）-Cy，其中A是一种含有7、8或9个环原子的二氮杂双环核，可从以下选择：2,6-二氮杂双环[3.2.0]庚烷；3,6-二氮杂双环[3.ZO]庚烷；2,7-二氮杂双环[4.2.0]辛烷；3,7-二氮杂双环[4.2.0]辛烷；3,8-二氮杂双环[4.2.0]辛烷；2,7-二氮杂双环[3.3.0]辛烷；2,7-二氮杂双环[4.3.0]壬烷；2,8-二氮杂双环[4.3.0]壬烷；3,7-二氮杂双环[4.3.0]壬烷；3,8-二氮杂双环[4.3.0]壬烷；3,9-二氮杂双环[4.3.0]壬烷；2,6-二氮杂双环[3.2.1]辛烷；3,6-二氮杂双环[3.2.1]辛烷；其中二氮杂双环通过两个环氮原子之一作为基团连接到所示的羰基上，使羰基与环氮形成酰胺键；Cy是一个杂环芳基基团；这些化合物表现出对中枢神经系统（CNS）的α402亚型的神经元乙酰胆碱受体的选择性和高亲和力。这些化合物和组合物可用于治疗和/或预防各种疾病或疾病，特别是CNS疾病。这些化合物被认为：（i）改变患者的大脑中乙酰胆碱能受体的数量，（ii）表现出神经保护作用，（iii）当以有效剂量使用时，不会产生明显的不良副作用，即明显的血压和心率升高，对胃肠道的明显负面影响以及对骨骼肌的明显影响。